Stocktoria
GOLDENWELL BIOTECH, INC. GWLL
GOLDENWELL BIOTECH, INC. (GWLL) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2024 revenue was $55 at a -539038.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GWLL | GOLDENWELL BIOTECH, INC. | 3/9 | — | — | — |
| SOWG | Sow Good Inc. | 1/9 | — | — | — |
| TRWD | Tradewinds Universal | 3/9 | — | — | — |
| NXMH | Next Meats Holdings, Inc. | 1/9 | — | — | — |
| BOF | BranchOut Food Inc. | 3/9 | -7.44 | — | — |
| CHSN | Chanson International Holding | 4/9 | 1.92 | 20.4 | +0.2% |
| BRLS | Borealis Foods Inc. | 4/9 | -16.21 | — | +8.2% |
About GOLDENWELL BIOTECH, INC.
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
FAQ
Is GWLL financially healthy?
GOLDENWELL BIOTECH, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does GWLL pay a dividend?
No, GOLDENWELL BIOTECH, INC. does not currently pay a dividend.
How profitable is GWLL?
In FY2024, GOLDENWELL BIOTECH, INC. had a net margin of -539038.2%.
Is GWLL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GOLDENWELL BIOTECH, INC.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2024-12-31. Facts plus Stocktoria's own computed scores — not investment advice.